Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Novartis and NasVax to pursue improved vaccines for influenza
April 2010
SHARING OPTIONS:

BASEL, SwitzerlandóNovartis Vaccines and Diagnostics Srl has signed an agreement with NasVax Ltd. to investigate the feasibility of developing improved vaccines, including vaccines for influenza and swine flu, the companies announced last month. The companies will conduct joint research using NasVax's VaxiSome adjuvant technology. Novartis also has an option to acquire a non-exclusive license to use the technology for the development of improved vaccines for certain indications in its existing vaccines portfolio. The option will be exercisable for a period of up to 14 months after the agreement's effective date and may be extended by Novartis' requests under certain conditions. The license entitles Novartis to milestone payments and royalties for the sales of vaccines it markets using VaxiSome. Specific financial details were not disclosed.  

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.